NRSNW Company Profile and Key Details

NeuroSense Therapeutics Ltd. earnings surprise history is a mixed track record. The quarter that ended March 31, 2026, missed forecasts by 210.73%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 4.8% in May 28, 2025.

NRSNW has shown sold momentum, gaining 40.64% over the past week and 127.27% over the past quarter, though year-to-date performance is up 127.27%. Average 10-day trading volume of 2.76 thousand shares is slightly above the 3-month average of 2.13 thousand, indicating heightened recent market interest.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) closed at $0.09 USD, losing -$0.02 (-15.94%) from the previous close of $0.11. The stock is currently mid-range between its 52-week high and low $0.08 and $0.30. With a market capitalization of about $2.24 million, NeuroSense Therapeutics Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.54). Key stats such as the average daily volume over the past year has been around 2.21 thousand shares, trading with heavier-than-usual volume. Headquartered in Herzliya, None, NeuroSense Therapeutics Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Alon Ben-Noon, the company employs approximately 17 people and listed since December 09, 2021. NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) shares are up 127.27% year-to-date Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows NeuroSense Therapeutics Ltd. trading at a premium to the broader market with a P/E of -2.93.

NeuroSense Therapeutics Ltd. trades at a P/E ratio of -2.93, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -12.21 indicating negative book value, which may reflect financial stress. The P/FCF stands at -9251.23, also below market averages.

Our AI price prediction model suggests that NeuroSense Therapeutics Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 76.41%, with price expected at $0.16 by November 21, 2023, within a range of $0.13 to $0.19